Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246071 | 0.91 | L3MBTL1 (0.56) | L3MBTL1LMNAMAPK1NPSR1ADORA1 | |
| SCHEMBL9056926 | 0.86 | LMNA (0.58) | L3MBTL1LMNAMAPK1NPSR1ADORA1 | |
| SCHEMBL28034943 | 0.86 | NR4A2 (0.55) | L3MBTL1LMNANPSR1ALDH1A1TP53 | |
| SCHEMBL9030278 | 0.86 | LMNA (0.61) | L3MBTL1LMNAMAPK1NPSR1ADORA1 | |
| SCHEMBL28034304 | 0.81 | CNR2 (0.56) | ALDH1A1CNR2CNR1HSD17B10 | |
| SCHEMBL27556132 | 0.81 | LMNA (0.56) | L3MBTL1LMNAMAPK1NPSR1ADORA1 | |
| SCHEMBL28774126 | 0.80 | PLA2G2A (0.49) | L3MBTL1LMNAMAPK1NPSR1ADORA1 | |
| SCHEMBL27740513 | 0.80 | LMNA (0.54) | L3MBTL1LMNAMAPK1NPSR1ADORA1 | |
| SCHEMBL28034936 | 0.79 | CDC25A (0.58) | CNR2CNR1 | |
| SCHEMBL28034295 | 0.79 | CDC25A (0.58) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116924964-A | Preparation method of tetrahydrocarbazole ring compound | 四川轻化工大学 | 2023-10-24 | — | — | CN | claimed |
| EP-1146905-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | Algos Pharmaceutical Corporation (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000029022-A1 | COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| WO-2000029023-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12383508-B2 | High-purity peg lipids and uses thereof | MODERNATX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250152518-A1 | PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4509118-A2 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | ModernaTX, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12151029-B2 | PEG lipids and uses thereof | MODERNATX, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240377399-A1 | COMPOSITIONS AND METHODS FOR MODULATING HYDROXYLATION OF ACC2 BY PHD3 | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-14 | — | — | US | disclosed |
| EP-3853305-B1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-11905525-B2 | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins | MODERNATX, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| WO-2001015744-A9 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | BRIGHAM & WOMENS HOSPITAL (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-1212101-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6376519-B1 | ANTIINFLAMMATORY AGENTS, ANTICANCER AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATION | 2002-04-23 | — | — | US | disclosed |
| EP-1146905-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | Algos Pharmaceutical Corporation (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001015744-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2000029022-A1 | COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000029023-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | disclosed |
| US-5604253-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | MERCK FROSST CANADA, INC. (CA) | 1997-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152518-A1 | PEG LIPIDS AND USES THEREOF | LIPA, LIPG, LIPC | L3MBTL1 1379/4885LMNA 1086/4885MAPK1 4115/4885 |
| US-11905525-B2 | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins | CD47, FCGR3B, MSR1 | L3MBTL1 386/4885LMNA 1808/4885MAPK1 3491/4885 |
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LNPEP, AUP1, PLTP | L3MBTL1 1280/4885LMNA 1776/4885MAPK1 1046/4885 |
| US-12151029-B2 | PEG lipids and uses thereof | LIPA, LIPG, LNPEP | L3MBTL1 1288/4885LMNA 1036/4885MAPK1 4078/4885 |
| US-12383508-B2 | High-purity peg lipids and uses thereof | LIPA, HDLBP, PLTP | L3MBTL1 1640/4885LMNA 2286/4885MAPK1 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.